在患有严重肌病的末期患者中使用皮下氨酸丁胺:一个病例报告
King Jane Ong1, Ryan Lester Rabe Abool1
1Palliative Care Service, Department of Geriatric Medicine, Changi General Hospital, Singapore.
Journal of pain & palliative care pharmacotherapy
|December 2, 2025
概括
在肌痛性骨髓灰质炎患者中管理死亡是具有挑战性的. 氨酸丁胺有效地治疗了临终期患者的死亡声,而没有恶化肌性症状.
科学领域:
- 抚慰性护理是一种缓解性护理.
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 死亡的声,以的呼吸为特征,在绝症中很常见.
- 抗胆固醇药物是通过减少分泌物来管理死亡声的标准.
- 肌痛性骨髓灰质炎 (MG) 患者需要乙胆酶抑制剂,抗胆固醇药可以对抗这些抗胆固醇药,造成治疗困境.
研究的目的:
- 举报一个成功管理死亡的病例,该病例发生在一个患有骨髓质疏松症的患者身上.
- 评估氨酸丁胺在这种特定患者群体中的疗效和安全性.
主要方法:
- 一个病例报告,一个终末期的病人患有死亡声和骨髓质疏松症.
- 用于死亡虫管理的素丁胺的管理.
- 监测死亡声症状和肌症状的情况.
主要成果:
- 氨酸丁胺有效地减少了呼吸道分泌物,解决了死亡的声.
- 患者的潜在肌痛性骨髓灰质炎症状保持稳定,并没有恶化.
- 这代表了一种新的方法来管理MG患者的死亡声.
结论:
- 氨酸丁胺可以是一个安全和有效的选择,用于管理死在患有严重肌痛性肌痛症的患者.
- 这一案例凸显了在复杂的息护理场景中需要仔细考虑药物相互作用的必要性.
- 可能需要进一步的研究,以在更广泛的MG人群中探索这种治疗方法.
相关概念视频
Myasthenia Gravis: Overview and Treatment
2.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.7K
Myasthenia Gravis: Diagnostic Tests
1.9K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.9K
Skeletal Muscle Relaxants: Therapeutic Uses
859
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
859
Depolarizing Blockers: Pharmocokinetics
553
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
553
Skeletal Muscle Relaxants: Adverse Effects
761
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Unlike...
761
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
1.4K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.4K


